Maze Therapeutics, Inc. (MAZE) AI Stock Analysis

• Market Cap: $519.43M
• Dividend Yield: N/A
• Average Volume (3M): 102.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 125
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 43,797,165
• 10 Day Avg. Volume: 137,124
• 30 Day Avg. Volume: 102,709
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $25.67
• Price Target Upside: 124.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 59 Neutral
• Price Target: ―

Maze Therapeutics shows strong financial performance with significant revenue and cash flow improvements, yet the negative equity presents a substantial risk. Technical indicators suggest potential weakness in stock momentum, and lack of valuation metrics prevents a comprehensive assessment. Overall, the stock's strengths in financial growth are tempered by balance sheet risks and technical analysis concerns.

Positive Factors

Drug Development

Maze is developing therapies in areas of significant unmet need and strategic interest, which should resonate favorably with investors.

Financial Stability

The company ended the quarter with $294.4M in cash and cash equivalents, which is expected to provide runway into 2H27.

Product Differentiation

MZE829 may be differentiated from other APOL1 inhibitors as it was designed to phenocopy a protective variant of the APOL1 gene and has demonstrated best-in-class potential in preclinical and early clinical data.

Negative Factors

Clinical Trials

The company remains on track to report initial proof-of-concept data from the HORIZON study in the first quarter of 2026.

Competition

MZE782 is de-risked by the positive results observed for Otsuka’s JNT-517, as both target the same mechanism.

Market Perception

Interest in the company is expected to pick up in the near term due to anticipated catalysts from both lead programs over the next few quarters.

Maze Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Maze Therapeutics, Inc. (MAZE) is a biotechnology company focused on translating genetic insights into novel therapeutic approaches for treating a range of diseases. Operating within the biotechnology and pharmaceutical sectors, Maze leverages its proprietary COMPASS platform to identify and validate genetic modifiers, which are then developed into potential therapeutic products. The company's core focus is on discovering genetic pathways that can be modulated to treat diseases with significant unmet medical needs.

How the Company Makes Money

Maze Therapeutics generates revenue through a combination of strategic partnerships, collaborations, and the development and commercialization of its own therapeutic products. The company partners with other biotech and pharmaceutical companies to co-develop therapies, often receiving milestone payments and royalties from these collaborations. Additionally, Maze invests in its proprietary drug development programs, aiming to bring its therapies to market and generate revenue from product sales. The company's revenue model is heavily reliant on research and development success, regulatory approvals, and the establishment of lucrative partnerships that provide funding and market access for its innovations.

Maze Therapeutics, Inc. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Maze Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MAZE	59 Neutral	$519.43M	―		―	―	―
SAGE	55 Neutral	$568.61M	―	-63.53%	―	-47.94%	30.94%
AKBA	49 Neutral	$950.74M	―	91.25%	―	-17.75%	-19.17%
SVRA	46 Neutral	$378.51M	―	-75.77%	―	―	-44.25%
Sector *	46 Neutral	C$194.28M	-4.22	-8.60%	2.64%	13.54%	-1.44%
OMER	40 Underperform	$187.50M	―	87.26%	―	―	-43.76%